What is Eikon Therapeutics, Inc. 's stock issuance proceeds?

Eikon Therapeutics, Inc. (EIKN) reported stock issuance proceeds of $277K in Q1 2026.

What does stock issuance proceeds mean?

Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

Cabot CorporationCBT

$6M+20.0%

BeldenBDC

$4.7M+23.0%

Travel + LeisureTNL

$4M+100%

Main Street CapitalMAIN

$134.28M+2,483%

Piper SandlerPIPR

$519K-65.1%

Alkami Technology, Inc.ALKT

$974K-36.0%

Operating income-$87.3M-22.3%

Net income-$83.0M-21.6%

EPS (diluted)-$2.46+90.9%

Cash & equivalents$161.2M-21.2%

Total debt$254.8M—

Total equity$550.7M+186%

Total assets$850.8M—

Operating cash flow-$89.8M-64.7%

CapEx$262.0K-98.8%

Free cash flow-$90.1M-17.1%

Market cap$521.35M—

Reported directly by Eikon Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.

The official record: Eikon Therapeutics, Inc. ’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Eikon Therapeutics, Inc. 's stock issuance proceeds?: Eikon Therapeutics, Inc. (EIKN) reported stock issuance proceeds of $277K in Q1 2026.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.